BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu Y, Zhou X, Wang X. Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities. J Hematol Oncol 2021;14:125. [PMID: 34404434 DOI: 10.1186/s13045-021-01134-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Cao X, Jin X, Zhang X, Utsav P, Zhang Y, Guo R, Lu W, Zhao M. Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies. Curr Treat Options Oncol 2023. [PMID: 36701037 DOI: 10.1007/s11864-023-01049-4] [Reference Citation Analysis]
2 Chen X, Hu S, Han Y, Cai Y, Lu T, Hu X, Chu Y, Zhou X, Wang X. Ferroptosis-related STEAP3 acts as predictor and regulator in diffuse large B cell lymphoma through immune infiltration. Clin Exp Med 2023. [PMID: 36682001 DOI: 10.1007/s10238-023-00996-4] [Reference Citation Analysis]
3 Tannoury M, Garnier D, Susin SA, Bauvois B. Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next? Cancers (Basel) 2022;14. [PMID: 36551511 DOI: 10.3390/cancers14246026] [Reference Citation Analysis]
4 Li Y, Liu X, Chang Y, Fan B, Shangguan C, Chen H, Zhang L, Zambelli F. Identification and Validation of a DNA Damage Repair-Related Signature for Diffuse Large B-Cell Lymphoma. BioMed Research International 2022;2022:1-24. [DOI: 10.1155/2022/2645090] [Reference Citation Analysis]
5 Guo H, Yang J, Wang H, Liu X, Liu Y, Zhou K. Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms. Front Immunol 2022;13:1017990. [DOI: 10.3389/fimmu.2022.1017990] [Reference Citation Analysis]
6 Li J, Wang Q, Lu H, Han Y, Jiang L, Qian W, Zhu M, Wang B, Min J, Hou Y, Xu S, Xiong Z, Liu H, Li Y, Chen C, Liu Y, Qian P. Graphdiyne oxide nanosheets exert anti-lymphoma effect by killing cancer stem cells and remodeling tumor microenvironment. Nano Today 2022;46:101622. [DOI: 10.1016/j.nantod.2022.101622] [Reference Citation Analysis]
7 Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer 2022;21:184. [PMID: 36163047 DOI: 10.1186/s12943-022-01657-y] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Liu Y, Song Y, Yin Q. Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia. Front Immunol 2022;13:962552. [DOI: 10.3389/fimmu.2022.962552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Li W, Wang F, Guo R, Bian Z, Song Y. Targeting macrophages in hematological malignancies: recent advances and future directions. J Hematol Oncol 2022;15:110. [PMID: 35978372 DOI: 10.1186/s13045-022-01328-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Maharaj K, Uriepero A, Sahakian E, Pinilla-ibarz J. Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies. Front Immunol 2022;13:943354. [DOI: 10.3389/fimmu.2022.943354] [Reference Citation Analysis]
11 Nie Y, Yun X, Zhang Y, Wang X. Targeting metabolic reprogramming in chronic lymphocytic leukemia. Exp Hematol Oncol 2022;11:39. [PMID: 35761419 DOI: 10.1186/s40164-022-00292-z] [Reference Citation Analysis]
12 Denizot Y, Braza M, Amin R. Editorial: B Cell Non-Hodgkin’s Lymphoma & Tumor Microenvironment Crosstalk: An Epigenetic Matter? Front Genet 2022;13:912737. [DOI: 10.3389/fgene.2022.912737] [Reference Citation Analysis]
13 Mahajan S, Aalhate M, Guru SK, Singh PK. Nanomedicine as a magic bullet for combating lymphoma. J Control Release 2022;347:211-36. [PMID: 35533946 DOI: 10.1016/j.jconrel.2022.05.002] [Reference Citation Analysis]
14 Zhai Y, Zhou X, Wang X. Novel insights into the biomarkers and therapies for primary central nervous system lymphoma. Ther Adv Med Oncol 2022;14:175883592210937. [DOI: 10.1177/17588359221093745] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Chen X, Zhou X, Wang X. m6A binding protein YTHDF2 in cancer. Exp Hematol Oncol 2022;11:21. [PMID: 35382893 DOI: 10.1186/s40164-022-00269-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Jiang Y, Zhang H, Wang J, Liu Y, Luo T, Hua H. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. J Hematol Oncol 2022;15:34. [PMID: 35331296 DOI: 10.1186/s13045-022-01252-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 26.0] [Reference Citation Analysis]
17 Manara F, Jay A, Odongo GA, Mure F, Maroui MA, Diederichs A, Sirand C, Cuenin C, Granai M, Mundo L, Hernandez-Vargas H, Lazzi S, Khoueiry R, Gruffat H, Herceg Z, Accardi R. Epigenetic Alteration of the Cancer-Related Gene TGFBI in B Cells Infected with Epstein-Barr Virus and Exposed to Aflatoxin B1: Potential Role in Burkitt Lymphoma Development. Cancers (Basel) 2022;14:1284. [PMID: 35267594 DOI: 10.3390/cancers14051284] [Reference Citation Analysis]
18 Li Y, Chen Z, Han J, Ma X, Zheng X, Chen J. Functional and Therapeutic Significance of Tumor-Associated Macrophages in Colorectal Cancer. Front Oncol 2022;12:781233. [PMID: 35186730 DOI: 10.3389/fonc.2022.781233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ogasawara M, Miyashita M, Yamagishi Y, Ota S. Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory malignant lymphoma. Leuk Lymphoma 2022;:1-5. [PMID: 35166650 DOI: 10.1080/10428194.2022.2038371] [Reference Citation Analysis]
20 Yu J, Sun H, Cao W, Song Y, Jiang Z. Research progress on dendritic cell vaccines in cancer immunotherapy. Exp Hematol Oncol 2022;11:3. [PMID: 35074008 DOI: 10.1186/s40164-022-00257-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
21 Yao S, Wang Z, Li L. Application of organic frame materials in cancer therapy through regulation of tumor microenvironment. Smart Materials in Medicine 2022. [DOI: 10.1016/j.smaim.2022.01.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]